Clinical Trials Logo

Colorectal Neoplasms Malignant clinical trials

View clinical trials related to Colorectal Neoplasms Malignant.

Filter by:

NCT ID: NCT06314971 Recruiting - Colorectal Cancer Clinical Trials

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

T1CR
Start date: March 15, 2023
Phase:
Study type: Observational

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

NCT ID: NCT06208371 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

Start date: January 15, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.

NCT ID: NCT06200831 Recruiting - Colorectal Cancer Clinical Trials

Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases

SYLMET
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.

NCT ID: NCT06067620 Not yet recruiting - Colorectal Cancer Clinical Trials

Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy

PRORHEM
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Robotic right hemicolectomy with intra-corporeal anastomosis may have better short-term recovery outcomes and decreased incidence of incisional hernia when compared to the laparoscopic actual standard of care, for similar safety outcomes.

NCT ID: NCT06050447 Recruiting - Colorectal Cancer Clinical Trials

Factors Affecting the Results of Treatment of Patients With Colorectal Cancer

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The study attempts to quantify the relative risks for mortality, anastomotic leakage and other early and late postoperative complications, recurrence rate, cancer-specific survival, recurrence-free survival after colorectal surgery for patients with colorectal cancer depending on the localization of the tumor.

NCT ID: NCT05853094 Recruiting - Colorectal Cancer Clinical Trials

Postoperative Effects of Different Enterostomy Approaches

Start date: June 23, 2023
Phase: N/A
Study type: Interventional

Exploring the effect of protective ileostomy compared with transverse colostomy on the occurrence of complications, the occurrence of serious side effects of adjuvant chemotherapy and disease recurrence in patients with low rectal cancer after radical surgery from the perspective of intestinal microecology.

NCT ID: NCT05353127 Completed - Colorectal Cancer Clinical Trials

Cardiopulmonary Exercise Test Data Averaging Methods and Preoperative Risk Assessment

Start date: April 12, 2022
Phase:
Study type: Observational

Cardiopulmonary exercise testing (CPET) is used for preoperative risk assessment in patients with colorectal cancer who need to undergo surgery. For presentation and interpretation purposes, CPET data are averaged by using a time- or breath-based average. It is uncertain to what extent differences in data averaging methods influence the numerical value of preoperative CPET-derived variables used for risk assessment. Therefore, the primary aim of this study is to investigate the influence of different CPET data averaging intervals on the numerical values of CPET-derived variables used for preoperative risk assessment in patients scheduled for elective colorectal cancer surgery. The secondary aim is to elucidate the impact of data-averaging intervals on classification of patients into a low- or high-risk category for postoperative complications based on known risk assessment thresholds.

NCT ID: NCT05279677 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Start date: August 12, 2022
Phase: Phase 2
Study type: Interventional

A single-arm, phase II study was designed to evaluate the efficacy and safety of fecal microbiota transplantation plus Sintilimab and Fruquintinib as the later line treatment in colorectal patients with advanced stages.

NCT ID: NCT05278351 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan(group A) compared to third-line regimens selected by researchers(group B) in the treatment of Ras wild-type recurrent and refractory metastatic colorectal cancer. This study will include Ras wild-type colorectal cancer that failed at least second-line treatment inthe past, including chemotherapy (oxaliplatin, irinotecan, fluorouracil) with or without targeted drugs (cetuximab, bevacizumab). 87 patients will be randomly assigned to group A and group B according to 2:1. The enrollment time is expected to be 12 months and the follow-up is expected to be 24 months.

NCT ID: NCT05163236 Completed - Colonoscopy Clinical Trials

Sensitivity of Fecal Immunochemical Test (FIT) for Colorectal Cancer (CRC) Screening

FITBACK
Start date: April 20, 2021
Phase:
Study type: Observational

Fecal immunochemical test (FIT) was introduced in France late 2015, FIT has better diagnostic accuracy for colorectal cancers (CRCs) than previous screening tests. Our primary objective was to evaluate the sensitivity of FIT and the proportion of interval cancer.